John Carter is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2919 W Swann Ave Ste 402
Tampa, FL 336094083
Telephone
813-696-1681Provider last certified this registry record 26 Sept 2024.
Clinical trials
- Treatment With Apremilast in Patients With Psoriatic Arthritis
Sponsor: University of South Florida
- A Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients
Sponsor: University of South Florida
- An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Sponsor: University of South Florida
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202538 payments$16,231openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202550 payments
- ANI Pharmaceuticals, Inc.Program year202531 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.7%Folate Analog Metabolic Inhibitor11%Methotrexate91%Methotrexate Sodium9%Part D<11 patientsTNF inhibitor10.2%Enbrel Sureclick47%Humira(Cf) Pen27%Cimzia (2 Pack)7%Humira Pen7%Simponi6%Enbrel6%Part D<11 patients+ 9 more classes in this area
Antiparasitic
18.5%Antimalarial18.5%Hydroxychloroquine Sulfate100%Part D≥104 patientsMetabolism & gastrointestinal
13.1%Corticosteroid7.8%Prednisone100%Part D≥63 patientsAminosalicylate3%Sulfasalazine63%Sulfasalazine Dr37%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2006–2007 per NIH RePORTER. The latest:
- Combination Antibotics as a Treatment for Chlamydia-Induced Reactive Arthritis
University of South Florida
FY2007$164,518R21AR053646 - Combination Antibotics as a Treatment for Chlamydia-Induced Reactive Arthritis
University of South Florida
FY2006$201,250R21AR053646
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”